organizations to lower Americans’ health care costs. Sec. 324. Protecting patients and improving the accuracy of provider directory information. Sec. 325. Ensuring enrollee access to cost-sharing information. Sec. 326. Access of individuals to protected health information. Sec. 327. Timely bills for patients. Sec. 328. Advisory group on reducing burden of hospital administrative requirements. Sec. 329. Data reporting to improve the transparency regarding how 340 B hospital covered entities provide care for patients. Sec. 330. Requiring 340 B drug discount program reports by DSH hospital covered entities on low-income utilization rate of outpatient hospital services. Sec. 331. Employer benefits reports. Sec. 332. Group health plan reporting requirements. Sec. 333. Government Accountability Office study on profit- and revenue-sharing in health care. Subtitle C—Prescription Drug Competition and Innovation Sec. 341. Expedited development and priority review for generic complex drug products. Sec. 342. Preventing blocking of generic drugs. Sec. 343. Ensuring timely access to generics. Sec. 344. Preemption of State barriers to the substitution of biosimilar products. Sec. 345. Increasing pharmaceutical options to treat an unmet medical need. Sec. 346. Provisional approval of new human drugs. Sec. 347. Consolidating exclusivity periods for drugs treating rare diseases and conditions. Sec. 348. Exclusivity period for brand name biological products. Sec. 349. Protecting access to biological products. Sec. 350. Streamlining the transition of biological products. Sec. 351. Regulation of manufacturer-sponsored copay contributions. Sec. 352. Antitrust exemption for private health insurer issuers to negotiate wholesale acquisition prices of prescription drugs purchased from drug manufacturers. Sec. 353. Biological product innovation. Sec. 354. Clarifying the meaning of new chemical entity. Sec. 355. Prompt approval of drugs related to safety information. Sec. 356. Conditions of use for biosimilar biological products. Sec.